ReviewTranslational psychiatry2022
Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics.
Review in Translational psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data.Wellcome open research · 2024Pooled it
- Animal Models for Drug Discovery in Schizophrenia: A Critical View from a Clinical Perspective.Pharmaceutical medicine · 2026Review
- Antipsychotic-like effects of the selective Rho-kinase 2 inhibitor KD025 in genetic and pharmacological mouse models of schizophrenia.Molecular psychiatry · 2026Article
- The Training Village: an open platform for continuous testing of rodents in cognitive tasks.bioRxiv : the preprint server for biology · 2026Article
- Filtering the noise: a cerebellar-centered framework for understanding and treating mental illness -a paradigm shift in psychiatry.Frontiers in psychiatry · 2026Article
- Plasma profiles of neurology-related proteins in at-risk mental state and first-episode psychosis: Associations with psychotic symptoms and cognitive performance.Brain, behavior, & immunity - health · 2025Article
- Novel Insights into Schizophrenia Treatment: Comprehensive Analysis Unveiling FGFR1 as a Promising Druggable Gene.Molecular neurobiology · 2025Article
- The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia.Journal of psychopharmacology (Oxford, England) · 2025Article
- The neuroreceptors and transporters underlying spontaneous brain activity.Communications biology · 2025Article
- Pharmacological reduction of reverse-translated hippocampal hyperactivity in mouse: relevance for psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Observational
- Cellular-Resolution and Bulk-Fluorescence Recordings of Calcium Activity Yield Reciprocal Readouts of In Vivo Drug Efficacy.Synapse (New York, N.Y.) · 2025Article
- Minor physical anomalies and social cognition in patients with schizophrenia and their first degree relatives.Frontiers in psychiatry · 2025Article
- Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment.BMC psychiatry · 2024Article
- GABAergic and inflammatory changes in the frontal cortex following neonatal PCP plus isolation rearing, as a dual-hit neurodevelopmental model for schizophrenia.Molecular neurobiology · 2024Article
- Regulation of Zbp1 by miR-99b-5p in microglia controls the development of schizophrenia-like symptoms in mice.The EMBO journal · 2024Article
- Drug targeting in psychiatric disorders - how to overcome the loss in translation?Nature reviews. Drug discovery · 2024Review
- Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives.Schizophrenia bulletin open · 2024Article
- Muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis: protocol for a systematic review and meta-analysis.F1000Research · 2024Article
- Captive ERVWE1 triggers impairment of 5-HT neuronal plasticity in the first-episode schizophrenia by post-transcriptional activation of HTR1B in ALKBH5-m6A dependent epigenetic mechanisms.Cell & bioscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite 50+ years of drug discovery, current antipsychotics have limited efficacy against negative and cognitive symptoms of schizophrenia, and are ineffective-with the exception of clozapine-against any symptom domain for patients who are treatment resistant. Novel therapeutics with diverse non-dopamine D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.